Thus, the low expression of ErbB2 and ErbB3 stabilized the PI3K/Akt signaling pathway in hematologic tumors (Table 1), thereby enabling compound 23 to exhibit more potent antitumor efficacy than against solid tumor cells. Here, ERBB3 is linked to hematopoietic and lymphoid cell neoplasm.